Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 92,447	$ 144,761
Accounts receivable, net	118,980	80,142
Inventories, net	108,539	94,491
Prepaid clinical development costs	2,791	586
Prepaid Inventory Costs	33,299	13,863
Other prepaid and current assets	4,408	4,155
Total current assets	360,464	337,998
Property and equipment, net	175	254
Right of use operating lease assets	3,325	5,513
Intangible assets	56	56
Total assets	364,020	343,821
Current liabilities:
Accounts payable	77,513	51,650
Convertible notes, net of issuance costs	54,863	54,575
Accrued clinical development costs	1,619	5,035
Accrued variable consideration	78,508	56,535
Other accrued liabilities	18,641	19,593
Royalty sale liability	94,826	47,586
Deferred revenue from collaborations	30,679	8,518
Operating lease liabilities	2,384	2,741
Total current liabilities	359,033	246,233
Convertible notes, net of issuance costs	97,128	96,745
Royalty sale liability	199,364	246,024
Long-term debt	151,653	140,971
Operating lease liabilities	767	2,570
Other long-term liabilities	7,436	0
Total liabilities	815,381	732,543
Commitments and contingencies (Note 5)
Stockholders’ deficit:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of September 30, 2025 and December 31, 2024	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 207,424,417 shares issued at September 30, 2025 and 197,846,661 shares issued at December 31, 2024	205	196
Additional paid-in capital	1,288,974	1,267,109
Treasury stock, at cost; 1,994,198 shares at September 30, 2025 and December 31, 2024	(54,998)	(54,998)
Accumulated deficit	(1,685,542)	(1,601,029)
Total stockholders’ deficit	(451,361)	(388,722)
Total liabilities and stockholders’ deficit	$ 364,020	$ 343,821